Assessing technical efficiency of HIV prevention interventions in four African countries: Methods of the orphea project
METHODS Our research methods were developed following: i) comprehensive review of methodologies on efficiency, ii) a peer review process, iii) consultations with governments and stakeholders and, iv) comments from implementing partners.
RESULTS In each country, the study sample consists of 60-80 health facilities (40 sites per clinical-based intervention and 15 sites for SW). All relevant input costs and intervention output data are being collected for 2011 or 2012; data sources include registers, reported data, and time-motion methods. Process quality is captured from exit interviews, vignettes, and by measuring the facility's attrition rate at each stage along the service delivery cascade for each intervention. Instruments and tools were adapted to the local contexts, while still allowing cross-country comparisons.
CONCLUSIONS Reliable data on costs and efficiency are critical to best inform budget allocation and financial decisions; this requires using rigorous estimation methods. This is one of the first studies to employ a complex package of survey methods to assess technical efficiency, especially in the context of multi-country HIV studies.
Learning Areas:Biostatistics, economics
Conduct evaluation related to programs, research, and other areas of practice
Planning of health education strategies, interventions, and programs
Discuss methods to measure technical efficiency and costs of HIV prevention interventions
Keyword(s): HIV/AIDS, Economic Analysis
Qualified on the content I am responsible for because: I have been the principal and co-principal investigator for multiple funded grants focusing on HIV/AIDS â epidemiology, male circumcision for HIV prevention and cost efficiency of interventions â and on epidemiology, practices and policies in neglected tropical diseases, and health systems and policy in several countries across Africa. My scientific interests are in evidence-based development of strategies for preventing and responding to infectious diseases including HIV, HPV and other neglected diseases of poverty.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.